Applauding the nation-wide lockdown to curb the unfold of coronavirus, ICMR Director General Balram Bhargava on Tuesday mentioned that the nation distributed the Covid-19 curve in such a means that it did not have many deaths and did not witness a huge peak. The feedback got here towards the backdrop of All India Institute of Medical Sciences (AIIMS) Director Dr Randeep Guleria’s assertion that India is witnessing a second wave of coronavirus in some areas.
“During the peak in Europe and the US, there were huge numbers of mortalities. We took learning from that and were able to distribute the curve in such a way that we did not have those deaths. This was attributed to the lockdown. We were able to distribute the curve and did not have a huge peak at all,” mentioned Bhargava, at a press convention, on being requested concerning the second wave.
India on Tuesday reported a spike of 83,000 new coronavirus circumstances within the final 24 hours, taking the nation’s whole case tally previous 49 lakh. The nation’s total Covid tally stands at 49,30,237 and 9,90,061 of them are energetic circumstances.
As far because the vaccine is worried, indigenous vaccines — Cadila and Bharat Biotech have accomplished Phase-1 and Serum Institute of India’s “wants to start the Phase-3 trial, which will commence after the clearance is given by the DCGI,” the ICMR chief mentioned.
Union Health Ministry Secretary Rajesh Bhushan, who was additionally at the press convention, mentioned nobody has presently utilized for the emergency authorisation of the vaccine.
Emergency authorisation is not just for vaccines however for medication, with an present provision within the Drugs and Cosmetic Act for this. It is an accelerated course of which allows the regulator to grant permission which is distinct from common advertising and marketing authorisation.
One instance is the US FDA giving emergency authorisation to Remdesivir. Similarly, emergency authorisation to Remdesivir was given by the India regulator too.
About the Sputnik vaccine, Bhushan mentioned: “Russia has a good history of vaccine manufacturing and hence, we assume that this vaccine is also good. There is a dialogue going on between the high-level committee of the governments of India and Russia. We are trying to work out its mechanism.”
Sputnik V, an adenovirus vector-based vaccine, was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, together with the Russian Direct Investment Fund and was registered on August 11.
Earlier, NITI Aayog member, Dr. V.Okay. Paul had mentioned that the Russian authorities has sought India’s assist in manufacturing the Sputnik V vaccine and in addition to conduct Phase-Three trials or bridging research within the nation.
(With IANS Inputs)